文献速递冠心病心律失常

心肌纤维化可预测冠心病患者心脏性猝死

Myocardial Fibrosis as a Predictor of Sudden Death in Patients With Coronary Artery Disease.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

本回顾性研究纳入979例冠心病患者,评估心血管磁共振显示的心肌纤维化视觉评估(MFVA)及灰区纤维化(GZF)质量与心脏性猝死(SCD)和室性心律失常(VAs)的关系。中位随访5.82年,MFVA与SCD和心律失常复合终点强烈相关,GZF3SD质量>5.0g者风险更高,且关联强度优于左心室射血分数(LVEF)<35%。结论提示在选择植入式心律转复除颤器(ICD)患者时,评估MFVA并量化GZF3SD质量可能优于LVEF。

要点

  • 冠心病患者中心肌纤维化视觉评估与SCD和VAs强烈相关。
  • GZF3SD质量>5.0g者SCD和心律失常风险显著升高。
  • 纤维化指标对SCD的预测强度优于LVEF<35%。

核心结论

  • 在冠心病患者中,MFVA联合量化GZF3SD质量与SCD和VAs的关联强于LVEF。
  • 选择ICD患者时,评估MFVA后量化GZF3SD质量可能优于LVEF。

研究设计与样本

  • 回顾性研究,纳入979例冠心病患者,平均年龄65.8±12.3岁。
  • 评估MFVA及MFVA患者中GZF质量,分析其与SCD及SCD或VAs复合终点的关系。
  • 中位随访5.82年(四分位距4.1至7.3年)。

主要发现

  • 随访期间29例(2.96%)发生SCD,80例(8.17%)达到心律失常复合终点。
  • 全队列中MFVA与SCD相关(HR 10.1;95%CI 1.42至1278.9),与心律失常终点相关(HR 28.0;95%CI 4.07至3525.4)。
  • 竞争风险分析中LVEF<35%与SCD关联较弱(sHR 2.99;95%CI 1.42至6.31),与心律失常终点sHR 4.71(95%CI 2.97至7.47)。
  • MFVA亚组(n=832)中GZF3SD>5.0g与SCD相关(sHR 10.8;95%CI 3.74至30.9),与心律失常终点相关(sHR 7.40;95%CI 4.29至12.8)。
  • 该亚组中LVEF<35%与SCD关联较弱(sHR 2.62;95%CI 1.24至5.52),与心律失常终点sHR 4.14(95%CI 2.61至6.57)。

关键数值与推荐

  • MFVA定义为视觉评估存在心肌纤维化。
  • GZF3SD采用3SD方法量化,阈值>5.0g。
  • LVEF<35%作为比较指标。

临床怎么用

  • 在冠心病患者ICD选择中,可考虑评估MFVA并量化GZF3SD质量,而非仅依赖LVEF。
  • GZF3SD质量>5.0g提示SCD和VAs风险显著升高,需加强监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The "gray zone" of myocardial fibrosis (GZF) on cardiovascular magnetic resonance may be a substrate for ventricular arrhythmias (VAs). OBJECTIVES: The purpose of this study was to determine whether GZF predicts sudden cardiac death (SCD) and VAs (ventricular fibrillation or sustained ventricular tachycardia) in patients with coronary artery disease (CAD) and a wide range of left ventricular ejection fractions (LVEFs). METHODS: In this retrospective study of CAD patients, the presence of myocardial fibrosis on visual assessment (MFVA) and GZF mass in patients with MFVA were assessed in relation to SCD and the composite, arrhythmic endpoint of SCD or VAs. RESULTS: Among 979 patients (mean age [± SD]: 65.8 ± 12.3 years), 29 (2.96%) experienced SCD and 80 (8.17%) met the arrhythmic endpoint over median 5.82 years (interquartile range: 4.1 to 7.3 years). In the whole cohort, MFVA was strongly associated with SCD (hazard ratio: 10.1; 95% confidence interval [CI]: 1.42 to 1,278.9) and the arrhythmic endpoint (hazard ratio: 28.0; 95% CI: 4.07 to 3,525.4). In competing risks analyses, associations between LVEF <35% and SCD (subdistribution hazard ratio [sHR]: 2.99; 95% CI: 1.42 to 6.31) and the arrhythmic endpoint (sHR: 4.71; 95% CI: 2.97 to 7.47) were weaker. In competing risk analyses of the MFVA subcohort (n = 832), GZF using the 3SD method (GZF3SD) >5.0 g was strongly associated with SCD (sHR: 10.8; 95% CI: 3.74 to 30.9) and the arrhythmic endpoint (sHR: 7.40; 95% CI: 4.29 to 12.8). Associations between LVEF <35% and SCD (sHR: 2.62; 95% CI: 1.24 to 5.52) and the arrhythmic endpoint (sHR: 4.14; 95% CI: 2.61 to 6.57) were weaker. CONCLUSIONS: In CAD patients, MFVA plus quantified GZF3SD mass was more strongly associated with SCD and VAs than LVEF. In selecting patients for implantable cardioverter-defibrillators, assessment of MFVA followed by quantification of GZF3SD mass may be preferable to LVEF.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Zegard A, Okafor O, de Bono J, et al. Myocardial Fibrosis as a Predictor of Sudden Death in Patients With Coronary Artery Disease. J Am Coll Cardiol. 2021. PMID: 33413938. doi:10.1016/j.jacc.2020.10.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。